306.90 +25.35 (9.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
306.9
Today’s High
306.9
52 Week Low
272.05
52 Week High
605.0
281.80 0.00 (0.00%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
280
Today’s High
286.05
52 Week Low
272
52 Week High
606
Key Metrics
- Market Cap (In Cr) 2471.68
- Beta 1
- Div. Yield (%) 0.39
- P/B 1.36
- TTM P/E 155.16
- Peg Ratio 2.02
- Sector P/E 26.42
- D/E 0.45
- Open Price 306.9
- Prev Close 281.55
Analysis
Price Analysis
-
1 Week2.8%
-
3 Months-27.8%
-
6 Month-34.45%
-
YTD-46.79%
-
1 Year-49.58%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
1 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 1
- Buy
- 0
- Strong Buy
- 0
Shilpa Medicare News
Stocks to Watch: HCL Tech, Axis Bank, Shilpa Medicare, Mindtree, Delta Corp
2 min read . 13 Jul 2022
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 1145.52
- Selling/ General/ Admin Expenses Total
- 425.8
- Depreciation/ Amortization
- 79.8
- Other Operating Expenses Total
- 16.47
- Total Operating Expense
- 1017.92
- Operating Income
- 127.61
- Net Income Before Taxes
- 102.26
- Net Income
- 60.66
- Diluted Normalized EPS
- 6.75
- Period
- 2022
- Total Assets
- 2875.5
- Total Liabilities
- 1053.3
- Total Equity
- 1822.19
- Tangible Book Valueper Share Common Eq
- 158.73
- Period
- 2022
- Cashfrom Operating Activities
- 105.13
- Cashfrom Investing Activities
- -285.5
- Cashfrom Financing Activities
- 82.86
- Net Changein Cash
- -97.51
- Period
- 2021
- Total Revenue
- 901.13
- Selling/ General/ Admin Expenses Total
- 352.74
- Depreciation/ Amortization
- 53.98
- Other Operating Expenses Total
- 21.09
- Total Operating Expense
- 721.98
- Operating Income
- 179.15
- Net Income Before Taxes
- 195.05
- Net Income
- 147.78
- Diluted Normalized EPS
- 12.59
- Period
- 2021
- Total Assets
- 2632.37
- Total Liabilities
- 1153.7
- Total Equity
- 1478.67
- Tangible Book Valueper Share Common Eq
- 137.55
- Period
- 2021
- Cashfrom Operating Activities
- 47.07
- Cashfrom Investing Activities
- -404.28
- Cashfrom Financing Activities
- 436.37
- Net Changein Cash
- 79.03
- Period
- 2020
- Total Revenue
- 907.91
- Selling/ General/ Admin Expenses Total
- 314.9
- Depreciation/ Amortization
- 43.78
- Other Operating Expenses Total
- 13.55
- Total Operating Expense
- 735.91
- Operating Income
- 172
- Net Income Before Taxes
- 188.05
- Net Income
- 156.15
- Diluted Normalized EPS
- 19.15
- Period
- 2020
- Total Assets
- 1986.13
- Total Liabilities
- 656.77
- Total Equity
- 1329.36
- Tangible Book Valueper Share Common Eq
- 132.29
- Period
- 2020
- Cashfrom Operating Activities
- 123.72
- Cashfrom Investing Activities
- -288.85
- Cashfrom Financing Activities
- 175.5
- Net Changein Cash
- 10.2
- Period
- 2019
- Total Revenue
- 733.39
- Selling/ General/ Admin Expenses Total
- 245.4
- Depreciation/ Amortization
- 42.06
- Other Operating Expenses Total
- 10.98
- Total Operating Expense
- 639.11
- Operating Income
- 94.28
- Net Income Before Taxes
- 135.68
- Net Income
- 112.26
- Diluted Normalized EPS
- 15.75
- Period
- 2019
- Total Assets
- 1610.02
- Total Liabilities
- 412.44
- Total Equity
- 1197.58
- Tangible Book Valueper Share Common Eq
- 123.81
- Period
- 2019
- Cashfrom Operating Activities
- 138.76
- Cashfrom Investing Activities
- -188.15
- Cashfrom Financing Activities
- 10.06
- Net Changein Cash
- -39.47
- Period
- 2018
- Total Revenue
- 791.53
- Selling/ General/ Admin Expenses Total
- 204.02
- Depreciation/ Amortization
- 37.22
- Other Operating Expenses Total
- 12.4
- Total Operating Expense
- 677.36
- Operating Income
- 114.18
- Net Income Before Taxes
- 136.77
- Net Income
- 105.24
- Diluted Normalized EPS
- 12.92
- Period
- 2018
- Total Assets
- 1499.13
- Total Liabilities
- 414.1
- Total Equity
- 1085.03
- Tangible Book Valueper Share Common Eq
- 116.27
- Period
- 2018
- Cashfrom Operating Activities
- 44.92
- Cashfrom Investing Activities
- -8.76
- Cashfrom Financing Activities
- -60.91
- Net Changein Cash
- -26.15
- Period
- 2017
- Total Revenue
- 783.81
- Selling/ General/ Admin Expenses Total
- 176.68
- Depreciation/ Amortization
- 30.64
- Other Operating Expenses Total
- 11.69
- Total Operating Expense
- 657.34
- Operating Income
- 126.47
- Net Income Before Taxes
- 146.49
- Net Income
- 107.58
- Diluted Normalized EPS
- 13.83
- Period
- 2017
- Total Assets
- 1472.21
- Total Liabilities
- 485.31
- Total Equity
- 986.9
- Tangible Book Valueper Share Common Eq
- 109.96
- Period
- 2017
- Cashfrom Operating Activities
- 37.48
- Cashfrom Investing Activities
- -262.23
- Cashfrom Financing Activities
- 312.7
- Net Changein Cash
- 92.92
- Period
- 2022-09-30
- Total Revenue
- 262.91
- Selling/ General/ Admin Expenses Total
- 73.56
- Depreciation/ Amortization
- 23.31
- Other Operating Expenses Total
- 60.7
- Total Operating Expense
- 274.02
- Operating Income
- -11.11
- Net Income Before Taxes
- -22.39
- Net Income
- -18.66
- Diluted Normalized EPS
- -2.15
- Period
- 2022-09-30
- Total Assets
- 2982.84
- Total Liabilities
- 1186
- Total Equity
- 1796.84
- Tangible Book Valueper Share Common Eq
- 152.55
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 66.11
- Cashfrom Investing Activities
- -141.42
- Cashfrom Financing Activities
- 97.31
- Net Changein Cash
- 22
- Period
- 2022-06-30
- Total Revenue
- 261.16
- Selling/ General/ Admin Expenses Total
- 72.86
- Depreciation/ Amortization
- 22.42
- Other Operating Expenses Total
- 63.77
- Total Operating Expense
- 263.01
- Operating Income
- -1.85
- Net Income Before Taxes
- -4.07
- Net Income
- 0.85
- Diluted Normalized EPS
- 0.1
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 340.6
- Selling/ General/ Admin Expenses Total
- 73.43
- Depreciation/ Amortization
- 22.34
- Other Operating Expenses Total
- 79.88
- Total Operating Expense
- 289.33
- Operating Income
- 51.27
- Net Income Before Taxes
- 46.41
- Net Income
- 29.55
- Diluted Normalized EPS
- 3.42
- Period
- 2022-03-31
- Total Assets
- 2875.5
- Total Liabilities
- 1053.3
- Total Equity
- 1822.19
- Tangible Book Valueper Share Common Eq
- 158.73
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 105.13
- Cashfrom Investing Activities
- -285.5
- Cashfrom Financing Activities
- 82.86
- Net Changein Cash
- -97.51
- Period
- 2021-12-31
- Total Revenue
- 272.3
- Selling/ General/ Admin Expenses Total
- 67.63
- Depreciation/ Amortization
- 20.65
- Other Operating Expenses Total
- 68.16
- Total Operating Expense
- 247.86
- Operating Income
- 24.44
- Net Income Before Taxes
- 19.24
- Net Income
- 9.57
- Diluted Normalized EPS
- 1.13
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 295.27
- Selling/ General/ Admin Expenses Total
- 65.58
- Depreciation/ Amortization
- 19.18
- Other Operating Expenses Total
- 74.26
- Total Operating Expense
- 252.38
- Operating Income
- 42.89
- Net Income Before Taxes
- 31.45
- Net Income
- 19.96
- Diluted Normalized EPS
- 1.76
- Period
- 2021-09-30
- Total Assets
- 2698.24
- Total Liabilities
- 1200.13
- Total Equity
- 1498.11
- Tangible Book Valueper Share Common Eq
- 133.14
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 4.62
- Cashfrom Investing Activities
- -76.4
- Cashfrom Financing Activities
- -29.67
- Net Changein Cash
- -101.45
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day278.68
- 10 Day280.02
- 20 Day293.12
- 50 Day330.92
- 100 Day366.7
- 300 Day399.64
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 284.25
- 0
- 0
- 358.55
- 257
- 3175.75
- Strides Pharma Science
- 336.85
- 0
- 0
- 519.5
- 263.45
- 2982.7
- Shilpa Medicare
- 306.9
- 25.35
- 9
- 605
- 272.05
- 2471.68
- Marksans Pharma
- 57.55
- 0
- 0
- 64.9
- 38.7
- 2405.64
- Sequent Scientific
- 89.35
- 0
- 0
- 204.45
- 81.4
- 2231.27
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 26.75
- 2.89
- 15.57
- 26.97
- Strides Pharma Science
- -
- 1.26
- -0.14
- -0.17
- Shilpa Medicare
- 42.17
- 1.36
- 8.96
- 12.81
- Marksans Pharma
- 13.13
- 2.02
- 19.29
- 11.2
- Sequent Scientific
- 54.42
- 3.22
- 7.1
- 5.11
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 50.01%
- 43,409,715
- VISHNUKANT CHATURBHUJ BHUTADA
- 7.33%
- 6,365,610
- DHARMAVATI BHUTADA
- 7.15%
- 6,207,796
- RAVI KUMAR INNANI
- 4.62%
- 4,006,370
- SURAJ KUMAR INNANI
- 4.59%
- 3,980,695
- OM PRAKASH INANI
- 3.3%
- 2,867,691
- DEEPAK KUMAR INNANI
- 3.15%
- 2,733,960
- KANTADEVI INANI
- 2.93%
- 2,540,096
- KESHAV BHUTADA
- 2.3%
- 2,000,000
- MADHAV VISHNUKANT BHUTADA
- 2.3%
- 2,000,000
- RAMAKANT INNANI
- 1.73%
- 1,497,778
- VISHNUKANTH C BHUTADA (HUF)
- 1.54%
- 1,336,130
- TARADEVI INNANI
- 1.44%
- 1,249,998
- VISHNUKANTA INANI
- 1.4%
- 1,212,498
- BRIJGOPAL INNANI
- 1.35%
- 1,174,866
- NATAMAL INNANI
- 1.3%
- 1,131,232
- SHAKUNTALABAI INNANI
- 1.3%
- 1,129,186
- SAGAR INNANI
- 1.15%
- 1,000,000
- TRIVENI INANI
- 0.34%
- 294,810
- PRIYA INNANI
- 0.21%
- 180,696
- KAMALKISHORE INNANI
- 0.19%
- 165,236
- MANJULATHA INNANI
- 0.18%
- 157,546
- KEERTI INNANI
- 0.18%
- 155,021
- NAMRATA BHUTADA
- 0.03%
- 22,500
- Public Shareholding
- 49.99%
- 43,392,183
- Others
- 13.92%
- 12,082,941
- PIVOTAL ENTERPRISES PRIVATE LIMITED
- 2.53%
- 2,200,000
- PIVOTAL BUSINESS MANAGERS LLP
- 2.12%
- 1,840,000
- BLUE DAIMOND PROPERTIES PVT LTD
- 1.84%
- 1,600,000
- Others
- 4.82%
- 4,174,331
- THINK INDIA OPPORTUNITIES MASTER FUND LP
- 2.02%
- 1,750,000
- MALABAR SELECT FUND
- 1.8%
- 1,561,658
- MALABAR INDIA FUND LIMITED
- 1.58%
- 1,375,760
- INDIA OPPORTUNITIES GROWTH FUND LTD - PINEWOOD STR
- 1.19%
- 1,036,615
- Others
- 4.39%
- 3,803,664
- SUNDAR IYER
- 1.15%
- 1,000,000
- ANANDKUMAR RAMESH GUPTA
- 1.08%
- 937,287
- Others
- 2.8%
- 2,426,697
- TA FII INVESTORS LIMITED
- 3.48%
- 3,025,000
- AMAL N PARIKH
- 1.95%
- 1,690,578
- Others
- 0.44%
- 387,438
- Others
- 1.01%
- 879,320
- HUF
- 0.67%
- 581,499
- Clearing Members
- 0.08%
- 73,477
- Trusts
- 0%
- 1,500
- Others
- 0.75%
- 648,203
- Others
- 0.33%
- 283,124
- Others
- 0.04%
- 31,077
- Others
- 0%
- 2,000
- Others
- 0%
- 14
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 11-Nov-22
- Quarterly Results
- 11-Aug-22
- Quarterly Results
- 23-May-22
- Audited Results & Dividend
- 08-Feb-22
- Quarterly Results
- 29-Oct-21
- Quarterly Results
- 14-Oct-21
- Preferential issue of shares
- 14-Aug-21
- Quarterly Results
- 31-May-21
- Audited & Quarterly Results
- 13-Feb-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 27-May-22
- 26-Apr-22
- COM
- 16-Mar-22
- 14-Feb-22
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 23-May-22
- -
- 19-Sept-22
- 1.1
- 31-May-21
- -
- 20-Sept-21
- 1.1
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Shilpa Medicare
- Industry Biotechnology & Drugs
- ISIN INE790G01031
- BSE Code 530549
- NSE Code SHILPAMED
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. It is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
MANAGEMENT
- Alpesh Dalal Chief Financial Officer
- Ritu Tiwary Compliance Officer, Company Secretary
- Vishnukant Bhutada Managing Director, Executive Director
- Sharath Kalakota Whole-Time Director
Company Summary
SHILPA MEDICARE SUMMARY
Shilpa Medicare is trading 9.00% upper at Rs 306.90 as compared to its last closing price. Shilpa Medicare has been trading in the price range of 306.9 & 306.9. Shilpa Medicare has given -46.79% in this year & 2.8% in the last 5 days.
Shilpa Medicare has TTM P/E ratio 155.16 as compared to the sector P/E of 26.42. There are 1 analysts who have initiated coverage on Shilpa Medicare. There are 0 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of -18.66 Crores in its last quarter.
Listed peers of Shilpa Medicare include Advanced Enzyme Technologies (0%), Strides Pharma Science (0%), Shilpa Medicare (9%) etc.
FAQs about Shilpa Medicare
Shilpa Medicare is trading at 306.90 as on 1 Dec, 2022 9:07:14 AM. This is 9.00% upper as compared to its previous closing price of 281.55
The market capitalization of Shilpa Medicare is 2471.68 Cr as on 1 Dec, 2022 9:07:14 AM.
The average broker rating on Shilpa Medicare is Hold. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 1 analysts have given a hold rating
- 0 analysts have given a buy rating
- 0 analysts have given a strong buy rating
The 52 wk high for Shilpa Medicare is 605.0 whereas the 52 wk low is 272.05
Shilpa Medicare can be analyzed on the following key metrics -
- TTM P/E: 155.16
- Sector P/E: 26.42
- Dividend Yield: 0.39%
- D/E ratio: -
Shilpa Medicare reported a net profit of 60.66 Cr in 2022.
